美股市場個股詳情

BIIB 渤健公司

添加自選

217.510
+4.000+1.87%

收盤價 05/03 16:00 (美東)

217.800
+0.290+0.13%

盤後 18:08 (美東)

316.69億總市值27.19市盈率TTM

渤健公司股票討論區

登錄發表評論

QianmengYu

04/25 03:05

掛個196買

$渤健公司(BIIB.US)$ 今天不要再製造個新缺口了

已翻譯

Cow Moo-ney

04/24 21:12

Green day

Tesla, Visa and Boeing are popping in pre market after reporting their earnings.
Specifically for Tesla, it’s quite amazing that it is rallying off a very poor earnings.
Sometimes, the market rallies on bad earnings could be because the bad results weren’t as bad as previously feared. Sometimes, peope buy into the “future growth” theory.
Whether all these rebounds are dead cat bounces, it remains to be seen.
PS: definitely not complaining about this pop
$SPDR 標普500指數ETF(SPY.US)$$標普500指數(.SPX.US)$$Visa(V.US)$$波音(BA.US)$$德州儀器(TXN.US)$$渤健公司(BIIB.US)$$愛彼迎(ABNB.US)$$美國銀行(BAC.US)$$迪士尼(DIS.US)$$蘋果(AAPL.US)$$Meta Platforms(META.US)$$微軟(MSFT.US)$$英偉達(NVDA.US)$$台積電(TSM.US)$$超微電腦(SMCI.US)$$Coinbase(COIN.US)$$谷歌-A(GOOGL.US)$

Big Tech Earnings - More Sell-Off??

From YouTube

特斯拉2024Q1財報：通往何處的十字路口

Movers and Shakers

04/24 20:19

專欄Today's Morning Movers and Top Ratings: TSLA, V, UBER, ABNB and More

Morning Movers
Gapping up
$特斯拉(TSLA.US)$ stock soared 12% following the announcement of earlier releases for "more affordable" car versions, despite first-quarter results falling short of Wall Street estimates.
$AT&T(T.US)$ stock increased by 3.6% after reporting stronger-than-expected subscriber growth and surpassing free cash flow growth in the first quarter.
$Visa(V.US)$ stock grew 2.4% as the credit card company's second...

Moomoo News Global

03/04 22:15

專欄Eli Lilly's Donanemab Nears Approval Decision, Could This Be a Turning Point in Alzheimer's Treatment?

The pharma giant $禮來(LLY.US)$ is on the cusp of a significant breakthrough with its Alzheimer's drug, donanemab. Following the completion of its Phase 3 trials, donanemab is currently undergoing FDA review and has the potential to receive approval later this month. If approved, it would be the second anti-Aβ therapy for Alzheimer's disease to receive full clearance from the U.S. FD...

Moomoo AI

02/27 19:31

Despite significant insider buying, Biogen's performance last year was worse than the annualised loss of 6% over the last half decade. Investors are advised to ensure they are buying a high quality business, as Biogen is showing 2 warning signs in investment analysis.

Shareholders in Biogen (NASDAQ:BIIB) Are in the Red If They Invested Five Years Ago

Moomoo AI

02/14 02:19

Wedbush Securities analyst Laura Chico suggests that Wall Street needs to reset its projections for Leqembi, and Biogen's turnaround story remains a work in progress. Biogen's CEO, Chris Viehbacher, sees Alzheimer's as the core franchise of Biogen going forward.

Biogen Plunges as Alzheimer Drug's Slow Uptake Signals Reset

Moomoo AI

02/13 23:56

The company's new CEO, Christopher Viehbacher, believes Biogen is well positioned for sustainable growth, despite the disappointing results and weak guidance. However, the market response suggests investors are not as optimistic about the company's growth prospects.

Biogen Promised a Return to Growth. Why the Stock Is Dropping. -- Barrons.com

Moomoo AI

02/13 21:05

Biogen's disappointing Q4 2023 financials and projected 2024 revenue contraction suggest a bearish outlook. The decline in revenue and EPS, and flat core pharmaceutical revenue, indicate potential financial challenges.

Biogen Slips as Outlook Disappoints Amid Flat Leqembi Sales

Moomoo AI

02/13 20:31

Biogen's stock struggles are linked to the slow launch of Alzheimer's drug Leqembi, facing challenges like limited capacity at infusion centers and long neurologist wait times. A convenient under-the-skin injection version could outperform Eli Lilly's potential rival, donanemab.